Menu
No results found.
“Patience reduces risk more reliably than prediction.”
Weekly Share Price & Valuation Overview
H. Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. The company was founded in 1915 and is headquartered in Valby, Denmark.
- Growth + profitability: double-digit revenue and profit margins.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- ROA ≥7% shows efficient use of assets.
- Revenue growth ≥10% indicates solid top-line momentum.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Market Cap Total equity value of the company (share price × shares outstanding).
- DKK 39.55B
- Enterprise Value Operating value: market cap + total debt − cash.
- DKK 52.27B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- DKK 23.52B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- DKK 19.18B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- DKK 7.11B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- DKK 23.72
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 3.52
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 2.29%
- Shares Outstanding
- 792.43M
- Float Shares
- 306.70M
- Implied Shares Outstanding
- 1.01B
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
26.08%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
30.22%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
81.55%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
14.82%
- ROA Strong Return on assets: net income ÷ total assets.
-
7.39%
- ROE Return on equity: net income ÷ shareholder equity.
-
14.70%
- Revenue Growth Strong Year-over-year revenue growth.
-
10.50%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
24.40%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
25.50%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.08
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.56
- Total Cash Cash and equivalents.
- DKK 2.65B
- Total Debt Short + long-term interest-bearing debt.
- DKK 13.65B
- Net Debt Total debt − cash (negative = net cash).
- DKK 11.00B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 1.92
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- DKK 3.41B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- DKK 3.38B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
14.49%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
14.37%
- Cash Conversion (OpCF/EBITDA)
- 0.48
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.